An observational study in Influenza and Acute Respiratory Distress Syndrome, sponsored by University Hospital, Bordeaux. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-27.
Sponsored by University Hospital, Bordeaux · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Influenza, Human with a site in France — 11 open to participants now, 12 under way, 3 of them phase 3. Influenza, Human · France.
Among the 103 studies in Influenza, Human with a site in France, this one is the 19th largest by planned enrollment of the 24 observational ones that give a count, is one of 4 that started in 2024, is one of 24 observational ones, reaches primary completion later than 3 of the 11 other live ones, and was the 94th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →11 of the 103 studies in Influenza, Human with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
University Hospital, Caen · Sites in France
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–100
Hospices Civils de Lyon · Sites in France
Ages 18+ · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 65+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 21 · Phase 3 27 · Phase 4 8
First in 2005; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is below the median of 403 across 335 observational studies indexed under Influenza, Human.
Median enrollment 312 across the 79 interventional studies, 431 across the 24 observational. Of the 81 that completed or were terminated, 25 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 103 have an industry lead sponsor. The 10 most frequent:
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
University Hospital, Bordeaux has 1 study filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
5 of the studies in Influenza, Human with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06254313University Hospital, BordeauxThe Role of Cxcr4Hi neutrOPhils in InflueNza | 2026-12 |
| NCT07882186Assistance Publique - Hôpitaux de ParisAssessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region | 2027-03 |
| NCT06907667Centre Hospitalier Universitaire de NiceStudy of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure | 2027-03 |
| NCT06643039Hospices Civils de LyonNosocomial Respiratory Virus Infection | 2027-07-05 |
Add all 5 to your calendar (.ics) → With an account.
Among the 103 studies in Influenza, Human with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Influenza is still responsible for more than 650,000 deaths per year worldwide and no major improvements in patients' care has been made despite 50 years of research. Especially, there is no therapeutic strategy targeting the dysregulated host response. CXCR4-expressing neutrophils seem to be involved in the rupture of host resistance. The aim of this study is thus to compare the percentage of blood CXCR4-expressing neutrophils between influenza survivors and non-survivors.
Influenza is still responsible for more than 650,000 deaths per year worldwide and no major improvements in patients' care has been made despite 50 years of research. Most of severe influenza patients suffer from acute lung injury due to a dysregulated immune response. Neutrophils are involved in both host resistance and disease tolerance. Thanks to advances in technologies, the vast variety in neutrophils subpopulations has been revealed. In particular, the subpopulation of CXCR4-expressing neutrophils has been suggested to be involved in the rupture of disease tolerance in lung infections. Nevertheless, these data are from murine models and remain to be confirmed in humans. Moreover, the underlying mechanisms remain unknown as well as the place of primum movens, i.e. vascular or alveolar compartment. The aim of this study is thus to compare the percentage of blood CXCR4-expressing neutrophils between influenza survivors and non-survivors. Percentage of BAL CXCR4-expressing neutrophils will also be compared. To this aim, blood sampling and BAL within the 24 hours and at day 3 after admission to ICU, neutrophils isolation, immunostaining and flow cytometry acquisition will be performed within the 24 hours and at day 3 after admission to ICU. Mortality rate will be collected at Day 28 and Day 90.
The population of interest will be patients with acute respiratory distress syndrome according to the Berlin criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cause of ARDS:
Exclusion Criteria:
to BAL:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Person with influenza virus infection proven by a positive polymerase chain reaction test for the influenza ARDS group. Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample.
Other: Additional tubes and LBA
A person with a proven bacterial infection (105 colony-forming units/mL for tracheal aspirates and more than 104 colony-forming units/mL for BAL). Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample.
Other: Additional tubes and LBA
Person presenting with acute pancreatitis according to the 2013 international recommendations (typical pain, lipasemia above 3 times normal and/or abnormality on imaging). Or Person presenting with acute bacterial peritonitis based on a clinical diagnosis and bacteria isolated on peritoneal samples (RFE SFAR 2018). Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample.
Other: Additional tubes and LBA
4 Additional tubes taken when blood is drawn during treatment : EDTA tubes and 2 citrate tubes and bronchoalveolar fluid sample (LBA)
Biological
Percentage of blood CXCR4-expressing neutrophils within the 24 hours following admission to ICU for invasive mechanical ventilation.
Time frame: Day 1 after inclusion
Clinical
Mortality
Time frame: Day 28 after inclusion
Start is estimated for Dec 2024; primary completion for Dec 2026, 24 months later.
Of 98 non-industry observational studies under Influenza, Human, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 92. This study's planned 24 months is below that.
Counting every sponsor, half of 135 studies reached it within 23 months; a quarter within 7 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →